Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

ImmunoGen’s Mark Enyedy On Striking Deals – And Curing Cancer

Sep 26 2017

• By William Looney

Enyedy_Mark_1200 — Mark Enyedy

Related Content

A CASCADE Of Trouble For Seattle Genetics' AML Drug SGN-CD33A

Jun 19 2017

Cancer’s Next-Gen Smart Bomb: Who Will Be First To Weaponize?

May 22 2017

Related Companies

ImmunoGen, Inc.

Takeda Pharmaceutical Co. Ltd.

Sanofi Genzyme

Baxalta Incorporated

NPS Pharmaceuticals, Inc.

Roche Holding AG

CytomX Therapeutics, Inc.

Jazz Pharmaceuticals plc

Seagen Inc.

Debiopharm S.A.

Amgen, Inc.

Merck & Co., Inc.

Pfizer Inc.

Merck KGaA

Novartis AG

ViroPharma Inc.

Additional Topics

Deals ImmunoOncology M & A Leadership BioPharmaceutical C-Suite Speaks

More from Deal-Making

More from In Vivo

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window